CytoMed Therapeutics Limited – NASDAQ:GDTC
CytoMed Therapeutics Limited stock price today
$1.75
-1.14
-39.45%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
CytoMed Therapeutics Limited stock price monthly change
+42.37%
month
CytoMed Therapeutics Limited stock price quarterly change
+42.37%
quarter
CytoMed Therapeutics Limited stock price yearly change
-44.42%
year
CytoMed Therapeutics Limited key metrics
Market Cap | 29.54M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.41 |
Revenue | N/A |
EBITDA | -4.10M |
Income | -5.34M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCytoMed Therapeutics Limited stock price history
CytoMed Therapeutics Limited stock forecast
CytoMed Therapeutics Limited financial statements
| Jun 2022 | 0 | -729.06K | |
|---|---|---|---|
| Dec 2022 | 0 | -1.53M | |
| Jun 2023 | 0 | -1.61M | |
| Dec 2023 | 0 | -1.46M |
| 2025 | 690.90K | -3.53M | -511.08% |
|---|
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 13914925 | 746.07K | 5.36% |
|---|---|---|---|
| Jun 2023 | 13914925 | 746.07K | 5.36% |
| Sep 2023 | 12368870 | 1.12M | 9.09% |
| Dec 2023 | 12368870 | 1.12M | 9.09% |
| Jun 2022 | -400.57K | -309.17K | -28.1K |
|---|---|---|---|
| Dec 2022 | -693.47K | -30.69K | 813.59K |
| Jun 2023 | -1.55M | -12.81K | 8.20M |
| Dec 2023 | -1.02M | -2.08M | -78.42K |
CytoMed Therapeutics Limited alternative data
| Mar 2024 | 28 |
|---|---|
| Apr 2024 | 28 |
| May 2024 | 28 |
| Jun 2024 | 28 |
| Jul 2024 | 28 |
CytoMed Therapeutics Limited other data
-
What's the price of CytoMed Therapeutics Limited stock today?
One share of CytoMed Therapeutics Limited stock can currently be purchased for approximately $1.75.
-
When is CytoMed Therapeutics Limited's next earnings date?
Unfortunately, CytoMed Therapeutics Limited's (GDTC) next earnings date is currently unknown.
-
Does CytoMed Therapeutics Limited pay dividends?
No, CytoMed Therapeutics Limited does not pay dividends.
-
How much money does CytoMed Therapeutics Limited make?
CytoMed Therapeutics Limited has a market capitalization of 29.54M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 20.16% to 290.56K US dollars.
-
What is CytoMed Therapeutics Limited's stock symbol?
CytoMed Therapeutics Limited is traded on the NASDAQ under the ticker symbol "GDTC".
-
What is CytoMed Therapeutics Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CytoMed Therapeutics Limited?
Shares of CytoMed Therapeutics Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does CytoMed Therapeutics Limited have?
As Jul 2024, CytoMed Therapeutics Limited employs 28 workers.
-
When CytoMed Therapeutics Limited went public?
CytoMed Therapeutics Limited is publicly traded company for more then 2 years since IPO on 14 Apr 2023.
-
What is CytoMed Therapeutics Limited's official website?
The official website for CytoMed Therapeutics Limited is w2.cytomed.sg.
-
How can i contact CytoMed Therapeutics Limited?
CytoMed Therapeutics Limited can be reached via phone at +65 6250 7738.
CytoMed Therapeutics Limited company profile:
CytoMed Therapeutics Limited
w2.cytomed.sgExchange:
NASDAQ
Full time employees:
28
Industry:
Biotechnology
Sector:
Healthcare
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
1 Commonwealth Lane, No. 08-22
Singapore, 149544
Singapore, 149544
CIK: 0001873093
ISIN: SGXZ17669631
:
